Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia

Nineteen patients 1 month to <2 years of age with (n = 16) or at high risk of (n = 3) invasive candidiasis received anidulafungin for 5–35 days (3 mg/kg day 1, 1.5 mg/kg daily thereafter) followed by optional fluconazole (NCT00761267). Most treatment-emergent adverse events were mild/moderate, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Roilides, Emmanuel, Carlesse, Fabianne, Tawadrous, Margaret, Leister-Tebbe, Heidi, Conte, Umberto, Raber, Susan, Swanson, Robert, Yan, Jean L., Aram, Jalal A., Queiroz-Telles, Flavio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Williams & Wilkins 2020
Materias:
Antimicrobial Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182240/
https://www.ncbi.nlm.nih.gov/pubmed/32032174
http://dx.doi.org/10.1097/INF.0000000000002568
_version_ 1783526207246041088
author Roilides, Emmanuel
Carlesse, Fabianne
Tawadrous, Margaret
Leister-Tebbe, Heidi
Conte, Umberto
Raber, Susan
Swanson, Robert
Yan, Jean L.
Aram, Jalal A.
Queiroz-Telles, Flavio
author_facet Roilides, Emmanuel
Carlesse, Fabianne
Tawadrous, Margaret
Leister-Tebbe, Heidi
Conte, Umberto
Raber, Susan
Swanson, Robert
Yan, Jean L.
Aram, Jalal A.
Queiroz-Telles, Flavio
author_sort Roilides, Emmanuel
collection PubMed
description Nineteen patients 1 month to <2 years of age with (n = 16) or at high risk of (n = 3) invasive candidiasis received anidulafungin for 5–35 days (3 mg/kg day 1, 1.5 mg/kg daily thereafter) followed by optional fluconazole (NCT00761267). Most treatment-emergent adverse events were mild/moderate, and no treatment-related deaths occurred. End of intravenous therapy global response success rate was 68.8%. Pharmacokinetics were similar to adult patients.
format Online
Article
Text
id pubmed-7182240
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-71822402020-05-04 Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia Roilides, Emmanuel Carlesse, Fabianne Tawadrous, Margaret Leister-Tebbe, Heidi Conte, Umberto Raber, Susan Swanson, Robert Yan, Jean L. Aram, Jalal A. Queiroz-Telles, Flavio Pediatr Infect Dis J Antimicrobial Reports Nineteen patients 1 month to <2 years of age with (n = 16) or at high risk of (n = 3) invasive candidiasis received anidulafungin for 5–35 days (3 mg/kg day 1, 1.5 mg/kg daily thereafter) followed by optional fluconazole (NCT00761267). Most treatment-emergent adverse events were mild/moderate, and no treatment-related deaths occurred. End of intravenous therapy global response success rate was 68.8%. Pharmacokinetics were similar to adult patients. Williams & Wilkins 2020-04 2020-02-06 /pmc/articles/PMC7182240/ /pubmed/32032174 http://dx.doi.org/10.1097/INF.0000000000002568 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Antimicrobial Reports
Roilides, Emmanuel
Carlesse, Fabianne
Tawadrous, Margaret
Leister-Tebbe, Heidi
Conte, Umberto
Raber, Susan
Swanson, Robert
Yan, Jean L.
Aram, Jalal A.
Queiroz-Telles, Flavio
Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia
title Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia
title_full Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia
title_fullStr Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia
title_full_unstemmed Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia
title_short Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia
title_sort safety, efficacy and pharmacokinetics of anidulafungin in patients 1 month to <2 years of age with invasive candidiasis, including candidemia
topic Antimicrobial Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182240/
https://www.ncbi.nlm.nih.gov/pubmed/32032174
http://dx.doi.org/10.1097/INF.0000000000002568
work_keys_str_mv AT roilidesemmanuel safetyefficacyandpharmacokineticsofanidulafungininpatients1monthto2yearsofagewithinvasivecandidiasisincludingcandidemia
AT carlessefabianne safetyefficacyandpharmacokineticsofanidulafungininpatients1monthto2yearsofagewithinvasivecandidiasisincludingcandidemia
AT tawadrousmargaret safetyefficacyandpharmacokineticsofanidulafungininpatients1monthto2yearsofagewithinvasivecandidiasisincludingcandidemia
AT leistertebbeheidi safetyefficacyandpharmacokineticsofanidulafungininpatients1monthto2yearsofagewithinvasivecandidiasisincludingcandidemia
AT conteumberto safetyefficacyandpharmacokineticsofanidulafungininpatients1monthto2yearsofagewithinvasivecandidiasisincludingcandidemia
AT rabersusan safetyefficacyandpharmacokineticsofanidulafungininpatients1monthto2yearsofagewithinvasivecandidiasisincludingcandidemia
AT swansonrobert safetyefficacyandpharmacokineticsofanidulafungininpatients1monthto2yearsofagewithinvasivecandidiasisincludingcandidemia
AT yanjeanl safetyefficacyandpharmacokineticsofanidulafungininpatients1monthto2yearsofagewithinvasivecandidiasisincludingcandidemia
AT aramjalala safetyefficacyandpharmacokineticsofanidulafungininpatients1monthto2yearsofagewithinvasivecandidiasisincludingcandidemia
AT queiroztellesflavio safetyefficacyandpharmacokineticsofanidulafungininpatients1monthto2yearsofagewithinvasivecandidiasisincludingcandidemia

Ejemplares similares